Comparative Pharmacology
Head-to-head clinical analysis: CALCIUM DISODIUM VERSENATE versus DEPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALCIUM DISODIUM VERSENATE versus DEPEN.
CALCIUM DISODIUM VERSENATE vs DEPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium disodium edetate chelates heavy metals (e.g., lead, cadmium) forming stable, water-soluble complexes that are excreted renally, reducing metal burden and toxicity.
Penicillamine is a chelating agent that forms soluble complexes with heavy metals (e.g., copper, mercury, lead) and promotes their renal excretion. In rheumatoid arthritis, it reduces rheumatoid factor and immune complexes, and inhibits collagen cross-linking.
1-2 g intramuscularly or intravenously every 12 hours for 3-5 days, followed by 2-5 days off, repeating as needed.
250 mg orally 4 times daily, target dose 1000-1500 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life: 20-30 minutes for unchelated drug; lead-chelate complex half-life: 1-2 hours. Clinical context: Short half-life necessitates continuous or repeated dosing for sustained chelation.
1.5-4 hours; prolonged to 6-12 hours in renal impairment; clinical context: dosing interval adjustments needed in CKD.
Renal: >95% as chelated lead complex; biliary/fecal: negligible (<5%)
Renal: 50% as unchanged drug; biliary/fecal: minor, <5%.
Category C
Category C
Chelating Agent
Chelating Agent